.jpg)
An international consortium of researchers including Dr Eamon McCarron, Consultant and Clinical Lead in Adult Inherited Metabolic Disorders at Sheffield Teaching Hospitals NHS Foundation Trust, have produced a new framework for classifying 100 rare genetic disorders.
The updated classification will make it easier to diagnose patients with inherited lysosomal disease, interpret genetic results and identify groups of patients who might benefit from the same treatments or clinical trials.
Lysosomes are specialised structures within cells that break down and recycle cellular material. Traditionally, lysosomal disorders have largely been understood as conditions in which enzyme deficiencies cause material to accumulate within cells.
Lysosomal disease affects one in every 4,000 to 10,000 live births. Early detection allows treatment to start before permanent, irreversible damage takes hold.
Supporting timely diagnosis
Dr Eamon McCarron, Consultant and Clinical Lead in Adult Inherited Metabolic Disorders at Sheffield Teaching Hospitals NHS Foundation Trust, said:
"Lysosomal disorders are a group of rare but collectively common diseases, and their effects can be debilitating, impacting severely on quality of life and function, and, in some cases, are life-limiting and life-shortening. By bringing together 108 inherited disorders within a framework based on modern lysosomal biology, we hope to provide a clearer way of understanding how these diseases relate to one another.
"Crucially, this could support more precise, timely diagnosis, allow doctors to detect life-threatening, treatable lysosomal conditions before symptoms start and help researchers identify shared disease mechanisms that could become targets for new treatments. For ultra-rare conditions, grouping patients by shared biology could also help inform the design of future clinical trials. Genetic testing is also playing an increasingly important role in routine care, and it is hoped this definition will support the ambitions of the Ten-Year Health Plan to make a difference to the health of the nation through next generation sequencing technologies and expanding newborn screening programmes."
Sheffield Adult Inherited Metabolic Disorders
The Sheffield Adult Inherited Metabolic Disorders service is one of seven specialist adult inherited metabolic disorder services commissioned by NHS England and provides specialist care for people with rare inherited metabolic conditions across the region.
The study was co-led with Dr Karolina Stepien, Consultant in Adult Inherited Metabolic Diseases at Salford Royal Hospital, and brought together researchers and clinicians from across the UK and internationally, including the University of Sheffield, University of Oxford, University College London, University of Manchester, University Children's Hospital Zürich, Leiden University and the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the US National Institutes of Health.
